Microbot Medical Inc.

What they do

Microbot designs and develops robotic endoluminal surgery devices, focusing on the minimally invasive surgery market. Its sole product, the LIBERTY Endovascular Robotic Surgical System, is a compact, fully disposable robot intended to maneuver guidewires and catheters within the vasculature, targeting the peripheral vasculature market. The system received FDA clearance on September 4, 2025, and the company is ramping up manufacturing for units intended for sale.

Revenue drivers

• LIBERTY Endovascular Robotic Surgical System — The company's sole product, designed for remote manipulation of guidewires and catheters; no revenues recognized through December 31, 2025, with initial sales expected after FDA clearance.

Recent performance

For the six months ended June 30, 2026, the company reported revenues of $346,000 ($105,000 in Q1 and $241,000 in Q2), its first reported product sales after FDA clearance. Net losses for 2025 were $13.1 million, and operating cash flow was negative $13.0 million. As of June 30, 2026, total assets were $73.4 million, total liabilities $4.4 million, and shareholder equity $68.9 million. Cash and equivalents stood at $3.2 million.

Strategy

Management plans to commercialize the LIBERTY system, focusing on the peripheral interventional radiology market initially, with future versions targeting Interventional Cardiology and Interventional Neuroradiology. The company is ramping up inventory manufacturing for units intended for sale following FDA clearance. It is also evaluating compatibility with its NovaCross products and other instruments to enable a 'One & Done' approach. Sales, general and administrative expenses are expected to increase as it builds out marketing and sales teams and maintains compliance requirements.

Risks

• No revenue history — The company has not recognized any revenues through December 31, 2025, and may never generate significant revenues or achieve profitability.
• Dependence on sole product — The business depends heavily on successful commercialization of the LIBERTY system; any delays or failures would materially harm the company.
• Need for additional capital — The company expects to need additional funding to transition to a commercial enterprise; if unable to raise capital, it may delay or reduce commercialization efforts.
• Market acceptance and reimbursement — Customers may not adopt the product unless attractive pricing and adequate third-party reimbursement are established.

Outlook

Management expects to continue incurring significant operating losses for the foreseeable future as it conducts sales and marketing for LIBERTY and continues R&D. The company anticipates generating revenues only after successfully commercializing the system, and expects SG&A expenses to increase over the long term. Future funding will likely be required to sustain operations and build a commercial infrastructure.